指南与共识前列腺癌

晚期前列腺癌:AUA/SUO指南修正(2026)第二部分:转移性去势抵抗性前列腺癌的评估与管理

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.
指南 / 共识 · J Urol · 2026-07-16

美国泌尿外科学会(AUA)在2025年更新文献回顾(ULR)后,通过修正流程纳入2023年版指南发布以来的新证据。本文为两部分系列中的第二部分,聚焦转移性去势抵抗性前列腺癌(mCRPC)的评估与管理更新推荐。文献回顾纳入38项研究进行全文审查,发表于2022年3月16日至2025年8月26日之间。

要点

  • AUA/SUO指南修正基于2025年ULR,纳入38项新研究更新mCRPC管理推荐。
  • 本文为两部分系列的第二部分,专门讨论mCRPC的评估与治疗更新。
  • 非转移性去势抵抗性前列腺癌(nmCRPC)的现有推荐经审查后被认为仍然适用。

核心结论

  • 本修正第二部分提供了mCRPC治疗的新指导,并讨论了晚期前列腺癌评估与管理未来方向。
  • 经审查,关于非转移性去势抵抗性前列腺癌(nmCRPC)的额外指导被认为仍然适用。

研究设计与样本

  • 指南修正基于AUA更新文献回顾(ULR)流程,识别38项发表于2022年3月16日至2025年8月26日之间的研究进行全文审查。
  • 专家组基于更新审查制定证据与共识为基础的声明。

临床怎么用

  • 临床可参考本修正第二部分更新对mCRPC患者的评估与管理策略。
  • 对nmCRPC的现有指南推荐经审查后认为仍然适用,可继续沿用。

局限性

  • 随着诊断和治疗选择的不断发展,本指南将需要进一步审查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part II of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: The AUA/SUO Advanced Prostate Cancer Guideline was reviewed via the AUA ULR process, which identified 38 studies for full-text review that were published between March 16, 2022, and August 26, 2025. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate. RESULTS: The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of advanced prostate cancer. These updates are detailed herein. CONCLUSIONS: Part II of this Amendment provides new guidance on treatment of mCRPC and discusses future directions for the evaluation and management of advanced prostate cancer overall. Additional guidance regarding non-metastatic castration-resistant prostate cancer (nmCRPC) was deemed current following review. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Scarpato KR, Cookson MS, Dreicer R, et al. Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer. J Urol. 2026. PMID: 42462145. doi:10.1097/JU.0000000000005219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。